ifenprodil has been researched along with Parkinson Disease, Secondary in 4 studies
ifenprodil: NMDA receptor antagonist
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatments for Parkinson's disease based on replacement of lost dopamine have several problems." | 1.31 | Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat. ( Brotchie, JM; Nash, JE, 2002) |
| " Compound 11a also potentiated the effects of L-DOPA in a rat model of Parkinson's disease (the 6-hydroxydopamine-lesioned rat), dosed at 30 mg/kg orally." | 1.31 | Subtype-selective N-methyl-D-aspartate receptor antagonists: benzimidazalone and hydantoin as phenol replacements. ( Meltzer, LT; Schelkun, RM; Serpa, K; Whittemore, ER; Wise, LD; Woodward, RM; Yuen, PW, 2000) |
| "In animal models of Parkinson's disease, loss of striatal dopamine leads to enhanced excitation of striatal NR2B-containing NMDA receptors." | 1.31 | Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. ( Brotchie, JM; Crossman, AR; Fox, SH; Henry, B; Hill, MP; Hille, C; Maneuf, Y; McGuire, S; Nash, JE; Peggs, D, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nash, JE | 3 |
| Brotchie, JM | 3 |
| Hill, MP | 2 |
| Schelkun, RM | 1 |
| Yuen, PW | 1 |
| Serpa, K | 1 |
| Meltzer, LT | 1 |
| Wise, LD | 1 |
| Whittemore, ER | 1 |
| Woodward, RM | 1 |
| Fox, SH | 1 |
| Henry, B | 1 |
| Peggs, D | 1 |
| McGuire, S | 1 |
| Maneuf, Y | 1 |
| Hille, C | 1 |
| Crossman, AR | 1 |
4 other studies available for ifenprodil and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Dopamine; Dose-Response Relationsh | 2002 |
Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat.
Topics: Animals; Antiparkinson Agents; Binding, Competitive; Corpus Striatum; Dizocilpine Maleate; Dose-Resp | 1999 |
Subtype-selective N-methyl-D-aspartate receptor antagonists: benzimidazalone and hydantoin as phenol replacements.
Topics: Animals; Benzimidazoles; Electrophysiology; Excitatory Amino Acid Antagonists; Hydantoins; Hydrogen | 2000 |
Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Calli | 2000 |